The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

Anxiety and Parkinson's disease

Published Online:https://doi.org/10.1176/jnp.8.4.383

Anxiety disorders, particularly generalized anxiety, panic, and social phobia, occur in up to 40% of patients with Parkinson's disease (PD). This rate is higher than in normal or other disease comparison populations. Current evidence suggests that anxiety may not be a psychological reaction to the illness but rather may be linked to specific neurobiologic processes accompanying PD. Anxiety in PD often coexists with depression. The optimal pharmacologic treatment for anxiety in patients with PD has not been established, but available information about the use of anxiolytics in PD is reviewed. Further study of the relationship between anxiety and PD may provide an excellent opportunity to clarify the neurobiologic substrate of anxiety itself.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.